Skip to main content
Figure 5 | Orphanet Journal of Rare Diseases

Figure 5

From: Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study

Figure 5

Mean ± SD change over time in plasma/urine Gb 3 in the transition safety population. (a) Plasma Gb3 (nmol/g creatinine) and (b) urine Gb3 (nmol/mL); the dotted lines represent the annualized slope. Baseline mean ± SD plasma Gb3 and urine Gb3 values at the beginning of phase 1 were 3.61 ± 1.60 nmol/mL and 538.09 ± 681.27 nmol/g creatinine, respectively (both measured at study TKT023 week 25/26). Agalα, agalsidase alfa; CI, confidence interval; Gb3, globotriaosylceramide; SD, standard deviation; yr, year.

Back to article page